Quoin Pharmaceuticals Ltd. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 14, 2024. Quoin is a clinical-stage pharmaceutical company developing treatments for rare diseases. It has no approved products and has generated no revenue.
Business context and development
- Lead candidate QRX003 is a topical lotion in two U.S. clinical studies for Netherton Syndrome (NS). The company also describes QRX004 as a potential treatment for recessive dystrophic epidermolysis bullosa; QRX007 and QRX008 are earlier-stage programs subject to licensing options.
- Quoin reported five U.S. study sites actively recruiting and dosing patients. It plans to pursue U.S. and European commercialization itself if QRX003 is approved, with international distribution partnerships already established, but has not completed a formal pricing analysis.
- The company had four full-time employees at year-end and relies extensively on contract research, clinical, and manufacturing providers.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | None | None |
| General and administrative expense | $6.071 million | $6.585 million |
| Research and development expense | $3.308 million | $2.673 million |
| Total operating expenses | $9.379 million | $9.258 million |
| Net loss | $8.687 million | $9.381 million |
| Net cash used in operating activities | $7.864 million | $8.481 million |
- R&D expense increased 23.8%, primarily from QRX003 clinical development, manufacturing, and QUT research work. G&A fell 7.8%, principally due to lower legal, public-company, and insurance costs, partly offset by higher stock compensation.
- Net loss narrowed by $0.695 million. FY2023 included $0.695 million of interest income and no interest expense; FY2022 included $0.714 million of interest and financing expense and $0.416 million of income from a payable settlement. Operating expenses were slightly higher in 2023.
- At December 31, 2023, cash and cash equivalents were $2.401 million and short-term U.S. Treasury investments were $8.294 million, totaling $10.695 million. Current liabilities were $3.581 million; total liabilities were $6.505 million. These included $3.524 million due to officers and $1.146 million of accrued interest/financing expense related to 2020 notes. No product-sales margins are applicable.
- Accumulated deficit was $46.203 million. Management said available resources, including the subsequent financing described below, were expected to fund operations for at least one year from issuance of the financial statements. It also said additional funding will be needed; no assurance is given that financing will be available on acceptable terms.
Material changes, outlook, and risks
- Initial open-label QRX003 results announced in October 2023 covered six evaluable subjects: five reported absent or negligible itching at dosing completion; three showed improved skin appearance at completion, while the other three showed improvement at some point during the study. All six reported favorable impressions. These are early results from a small, uncontrolled study, not proof of efficacy.
- Following those results and no reported safety concerns in either study, FDA-cleared protocol amendments increased the double-blind study from 18 to 30 subjects and the open-label study from 10 to 20, and changed dosing from once daily to twice daily. In March 2024, FDA also cleared a request to lower the minimum enrollment age to 14.
- Management expects significant R&D spending and continued losses as studies advance. The filing provides no specific revenue, profitability, or approval-date guidance. Clinical success, recruitment, regulatory approval, manufacturing, and future capital access remain uncertain.
- After year-end, Quoin completed a March 7, 2024 securities offering for approximately $6.5 million gross and $5.6 million net proceeds. The deal included shares, pre-funded warrants, and Series D and E warrants exercisable at $1.60; existing warrants for up to 638,834 ADSs also had their exercise prices reduced to $1.60 and terms extended. These securities create potential dilution.
- A January 2024 agreement provides a potential equity line of up to $8 million, subject to conditions including shareholder approval; the company committed to issue purchase notices for at least $4 million if the facility commences. Sales under it were restricted for 180 days following the March offering.
- The Skinvisible license carries a single-digit royalty on net sales, 25% of sublicense royalty revenues, and a $5 million payment upon the first qualifying U.S. or EU approval. No material legal proceedings were reported. The 2023 financial statements received an unqualified audit opinion; management reported effective disclosure controls and internal control over financial reporting, but the auditor did not provide an ICFR attestation.
- Other significant risks include the company’s history of losses and dependence on financing; clinical and regulatory uncertainty; reliance on limited or single-source vendors; intellectual-property and commercialization challenges; potential Nasdaq listing compliance; and possible dilution. Quoin regained Nasdaq’s minimum bid-price compliance in August 2023.
Important facts for investors to verify
- Current cash runway and expected quarterly burn, taking account of the March 2024 net proceeds, study expansion, and any further financing needs.
- Enrollment, dosing, safety, and full results from both QRX003 studies, including how regulators view endpoints and the twice-daily regimen.
- Potential dilution from outstanding and newly issued warrants, the equity line’s conditions and minimum-purchase commitment, and the effect of the reverse splits on historical per-share comparisons.
- The amount, timing, and terms of officer-related liabilities and the outstanding accrued note interest; confirm whether these balances are expected to be repaid or otherwise settled.
- The status of QRX003 licensing and distribution arrangements, approval-dependent payments and royalties, and the company’s ability to fund development through a potential launch.